Objective:

To assess the acute and long-term toxicity profiles of hypofractionated radiotherapy (Hypo-RT) and ultra-hypofractionated radiotherapy (UHF-RT) in patients with localized prostate cancer, highlighting their clinical significance.

Key Findings:

• Hypo-RT shows similar acute and late genitourinary (GU) toxicity compared to conventional radiotherapy, with implications for treatment choice.
• Patient-reported outcomes indicate that patients often report more severe symptoms than physicians, highlighting the need for comprehensive assessment.
• Validated questionnaires like EPIC-50 and EORTC QLQ are essential for measuring quality of life and treatment-related symptoms, underscoring their importance in clinical practice.

Interpretation:

The findings suggest that while Hypo-RT is effective, careful monitoring of both physician-reported and patient-reported outcomes is crucial for understanding the full impact on patient quality of life, especially considering the limitations of current studies.

Limitations:

• The review does not provide a detailed meta-analysis of Hypo-RT as monotherapy, which could enhance understanding of its efficacy.
• The assessment of toxicity relies on available RCTs, which may not encompass all patient experiences, and potential biases in patient-reported outcomes should be considered.

Conclusion:

Hypo-RT presents a viable treatment option for localized prostate cancer with manageable toxicity profiles, emphasizing the importance of incorporating patient-reported outcomes in clinical assessments and the need for ongoing research.